INTRODUCTION
In the animal body the formation of new cells requires the synthesis of nucleic acids and for this purpose certain derivatives of pyrimidine bases (e.g., uracil, cytosine, and thymine) must be synthesized by, or supplied to, the parent cells. Accordingly, it would be reasonable to assume that significant interference with the formation or utilization of these pyrimidinecontaining compounds could profoundly affect the rate at which new cells are formed in various tissues. It is often assumed that a potent inhibitor of cellular reproduction should affect all tissues in a comparable manner; however, many factors influence to a variable degree the capacity of a compound to disturb the reproduction of various types of cells in a variety of tissues. Indeed, the moderate degree of selectivity already observed with certain well-recognized carcinostatic agents is indicative of significant variability, in different loci, in such factors as transport into cells, affinity for those enzymes which normally react with physiological intermediates, and the degree of metabolic alteration of such agents.
The results of earlier studies from these laboratories of the biological effects of analogs of the naturally occurring pyrimidines, orotic acid,' "' thymine, and its deoxyriboside,6" 7"8 encouraged us to attempt to obtain a compound capable of interfering specifically with the metabolism of uracilcontaining substances. Such a compound (or appropriate derivatives of it) could interfere not only with the synthesis of ribonucleic acids, but also with that of deoxyribonucleic acids, and with a sizable group of coenzymes containing either uracil or its derivative, cytosine.
For this purpose a most promising possibility, as suggested by earlier studies of 6-azathymine (6-methyl-as-triazine-3,5-dione) and its deoxyriboside,'17,8 was a comparable analog of uracil, namely, 6-azauracil (astriazine-3,5-dione), a substance with chemical structure and stability which made pertinent its biological investigation. Although prepared in 1947 for use in a study of chemical reaction mechanisms, the method of synthesis was not described in detail,20 and, therefore, a new procedure was evolved."' Studies by Handschumacher and Welch" of the effect of 6-azauracil (AzU) on a variety of microorganisms indicated that this analog is an effective inhibitor of cellular reproduction and that its action under certain conditions can be nullified by the natural metabolites: uracil and uridine (uracil riboside). Of especial significance to further applications of the analog was the finding that the utilization not only of exogenous, but also of endogenously formed derivatives of uracil was blocked by the antagonist. It has been shown that with Streptococcus faecalis 8043, an organism highly susceptible to inhibition by AzU, drug-resistant mutants are selected by AzU." The mechanism of this resistance is attributed' to the fact that among a significant population of S. faecalis cells there are individuals which possess no capacity to utilize free uracil and thus offer no pathway for the assimilation of AzU. Since such AzU-resistant cells can utilize uridine, it was reasoned that biochemical circumvention of this type of drugresistance should be possible through the use of AzU-riboside (AzUR). This compound, azauridine, was prepared both biologically and chemically9 and shown to be highly inhibitory to AzU-resistant bacteria. It should be mentioned, however, that resistance to AzUR also can be encountered in bacterial populations. Evidence that AzU enters the same pathways of metabolism as does uracil or uridine has been shown by the isolation from the acid-soluble fraction of microorganisms exposed to AzU-C14 of radioactive azauridine and its mono-, di-, and tri-phosphates; in addition, other derivatives of AzU are formed in small amounts.9"0 Tests of AzU in mice bearing various transplantable neoplasms, carried out collaboratively at Yale and the National Cancer Institute (Law), and also, independently, at the Wellcome Physiological Laboratories and in Czechoslovakia, showed that the analog, in doses exerting slight or no toxic effects on the host, appreciably inhibited the growth of such tumors as lymphomas L-1210, L-4946, L-5178, and sarcoma 180,' adenocarcinoma 755,2 Ehrlich ascites carcinoma,' and the plasma cell neoplasm 70429.'
Since the bacterial studies had suggested that inhibition of cellular reproduction requires the formation of ribose-containing derivatives of AzU, tests were made of the urine of mice receiving AzU and the presence of material behaving in all respects as AzUR was demonstrated.' Further-more, studies of sarcoma 180 cells reproducing in tissue culture showed that, although quite unaffected by AzU (in concentrations up to 5 ,umoles/ ml.), the growth of the neoplastic cells was inhibited by AzUR (0.01-0.02 ,umole/ml.), an effect prevented by uridine but not by uracil.' Even greater sensitivity to AzUR was obtained with L-5178 in tissue culture; not only were these cells insensitive to free AzU, but even to its deoxyriboside5 (the latter compound was prepared biosynthetically from AzU).' In these cellsystems,"0' and in S. faecalis,8 exposure of reproducing cells to led to extensive accumulation of radioactivity in the acid-soluble, but only to a very limited degree, if at all, in the nucleic acid fractions.
Since the chemical synthesis of AzUR is tedious and gives unsatisfactory yields, the conversion of AzU to AzUR was accomplished biologically using S. faecalis,9 and, more recently, through the use of modifications of a ribosidation procedure involving E. coli, described by Skoda et al. ' The present paper describes the remarkably higher activity of AzUR, in comparison with AzU, as an inhibitor of the growth of the lymphomatous neoplasms L-1210 and L-5178, and of sarcoma 180, in mice.
MATERIALS AND METHODS
The procedures used in these experiments have been described in detail elsewhere by Mautner and Jaffe ; only enough information is given herein to make the data intelligible. Studies with the two lymphomas were done in AKR X DBA/2 F, hybrid mice of either sex (Jackson Laboratories), while studies with sarcoma 180 were done in female SWR mice (Millerton Research Farm); in both cases the animals were 6-8 weeks old, weighed 18-25 g., and were given Purina Lab Chow and water ad libitum. Sarcoma 180, obtained aseptically from a donor mouse, was divided into pieces of about 1 mm.8; one of these was implanted subcutaneously with a trocar into the right axillary region of each mouse. The lymphomas were transferred subcutaneously (right flank) as a suspension of cells; each mouse was given, within experimental error, the same number of cells (1-3 X of the tumors of untreated control mice; with the S-180 mice, the length of the two largest perpendicular axes of the tumors was measured in situ (to 0.1 mm.) and the tumor volume was estimated, using the formula for determining the volume of a prolate spheroid, and the volumes obtained were compared to those of the tumors in the untreated control mice. In Table 1 the results are presented in terms of mean values, together with the standard error of each mean; the effectiveness of each dosage regimen is indicated by the approximate percentage of inhibition of tumor growth.
RESULTS
The results obtained are summarized in Table 1 . In addition, an experiment was carried out to test the effect of frequency of administration of AzUR on its efficacy. Earlier it had shown7 that AzU is maximally effective against L-1210 lymphomas when given for 6 days in the drinking water or when the total daily doses (15 mg./20-g. mouse/day) were given in three portions at 8-hour intervals (83 per cent inhibition). If the same total amount was given only once daily, the inhibition obtained was 41 per cent, while administration twice daily, at intervals compatible with a normal working day, 9 a.m. and 5 p.m., gave only 50 per cent inhibition. Since other evidence indicated that AzUR is excreted even more rapidly than is AzU,* the relation between frequency of dosage of AzUR and its degree of carcinostatic effect was investigated (with L-5178-Y). It was found that insignificant inhibitions of tumor growth were obtained when the drug was given less frequently than at 8-hour intervals.
DISCUSSION
The data obtained from the comparative studies of the effect of AzUR and AzU on the growth of mouse tumors L-1210, L-5178-Y and sarcoma 180 show clearly that, on a molar basis, the carcinostatic activity of the riboside is from 10 to 20 times that of AzU.
Although the inhibitory effect of AzU on the growth of sarcoma 180 is not dramatic, the effects of AzUR, in molar ratio of 1: 22 (AzUR: AzU), were clearly as great or greater than were those of the free base. Also, with L-1210 and L-5178-Y the comparisons of AzUR and AzU leave no doubt concerning the far greater potency of AzUR as an inhibitor of the very rapid growth of these lymphomas, which eventually cause a fatal leukemia. It is believed that the limited capacity of the mouse to convert AzU to * Preliminary experiments in collaboration with L. Peters and R. Volle, Department of Pharmacology, University of Kansas, have shown that, in the hen, renal tubular secretion contributes to the excretion of AzUR but not to that AzU. Preliminary studies in man with S. C. Finch, Department of Internal Medicine, Yale University School of Medicine, also have shown that AzUR is cleared more rapidly from the blood and excreted more rapidly by the kidney than is AzU. The rapid loss of unchanged AzUR from the blood and other tissues calls attention to the remarkable stability of this riboside and to the effect of ribosidation on the pathways of renal elimination of AzU. As is well known, the physiologically occurring ribosides are readily cleaved by nucleosidases and it is of considerable theoretical, as well as practical, interest that the enzymatically formed riboside of AzU, so closely analogous to uridine in structure, is so very resistant to attack by catabolic enzyme systems. The finding that ribosidation of AzU results in its more rapid removal from the blood, because of active renal tubular secretion in the kidneys, is certain to lead to studies of the effect on tubular secretion of ribosidation of other bases either foreign to the body or of physiological significance. From the more practical standpoint, investigation of the mechanism of the renal tubular secretion of AzUR might suggest a means of interfering with this pathway which would permit a reduction in the rate at which the presently exceedingly precious compound is lost from the blood and other tissues.
Finally, it may be stated that, should additional studies of AzUR offer promise of chemotherapeutic utility, there is reason to believe that the biological conversion of AzU to its riboside will be a practicable procedure, the cost of which should not be a serious limitation on the continued investigation of this new agent.
SUMMARY
Azauridine, the riboside of 6-azauracil, is shown to be a potent inhibitor of the growth in mice of lymphomas L-1210 and L-5178-Y (a new strain of L-5178), and of sarcoma 180. On a molar basis, azauridine is from 10 to 20 times as active as 6-azauracil, and, in the amounts required, exerts a negligible host toxicity. The rapid elimination of azauridine in the urine necessitates frequent administration of the compound, when given parenterally, but its remarkable stability and resistance to enzymatic degradation permit azauridine to be given as effectively by mouth (in the drinking water of mice) as by frequent parenteral injection.
